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Background: Hepatocellular carcinoma has a high mortality rate due to its rate of recurrence. Acyclic retinoid
prevents recurrence of hepatocellular carcinoma in patients after surgical removal of their primary tumors by
inducing apoptosis in hepatocellular carcinoma cells, although the molecular mechanisms of action are not
understood.
Methods: Human hepatocellular carcinoma cells in culture, as well as nude mice transplanted with hepatocellular
carcinoma cells and rats given with N-diethylnitrosamine were treated with acyclic retinoid. Changes in activated
caspase 3 and transglutaminase 2 (TG2) levels, Sp1 cross-linking and its activities, expression of epidermal growth
factor receptor, and apoptotic levels were measured.
Results: Acyclic retinoid simultaneously stimulated the activation of caspase 3, and the expression, nuclear
localization and crosslinking activity of TG2, resulting in crosslinking and inactivation of the transcription factor, Sp1,
thereby reducing expression of epidermal growth factor receptor and cell death in three hepatocellular carcinoma
cell lines. These effects were partially restored by a caspase inhibitor, transfection of antisense TG2, restoration of
functional Sp1, or an excess of epidermal growth factor. Nuclear expression of TG2 and crosslinked Sp1, as also
activated caspase 3 were found in both hepatocellular carcinoma cells transplanted into nude mice and cancerous
regions within the liver in N-diethylnitrosamine-induced hepatocarcinogenesis model in rats, following treatment of
animals with acyclic retinoid.
Conclusions: Treatment with acyclic retinoid produces a dual activation of caspase 3 and TG2 induced apoptosis
of hepatocellular carcinoma cells via modification and inactivation of Sp1, resulting in reduced expression of
epidermal growth factor receptor.
Background
Hepatocellular carcinoma (HCC) has high mortality rate
because of it frequent rate of recurrence [1]. Acyclic
retinoid (ACR), a synthetic retinoid, prevents the recur-
rence and development of HCC in patients after surgical
removal of the primary tumors by inducing apoptosis in
HCC cells [2,3]. Retinoid X receptor (RXR) a is highly
phosphorylated and loses its activity as a transcriptional
factor during carcinogenesis in HCC [4]. ACR prevents
this aberrant hyper-phosphorylation of RXRa by sup-
pressing the Ras-extracellular signal regulated kinase
(Erk) pathway, thereby restoring RXRa’s activity in
response to physiological concentrations of 9-cis retinoic
acid (9-cis RA) [5]. We therefore proposed that this
restoration of RXRa transcriptional activity is a basis for
ACR’s activity to control aberrant cell growth and
induce apoptosis. However, the possibility that genes
under the control of RARa/RXRv are upregulated by
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aberrant growth and/or inducing apoptosis, has not
been fully elucidated. ACR downregulates epidermal
growth factor receptor (EGFR) signals due to suppres-
sion of transforming growth factor (TGF) a in both
HCC cells and human squamous cell carcinoma cells
undergoing apoptosis [6,7]. ACR induces the expression
of interferon receptor, and also the expression and activ-
ity of signal transducer and activator of transcription
(STAT) 1 during suppression of cell growth and induc-
tion of HCC cell apoptosis [8]. However, it is unclear
whether these phenomena are dependent on the restora-
tion of RARa/RXRa.
Transglutaminase 2 (TG2) is a member of a family of
crosslinking enzymes that catalyze a post-translational
modification of proteins by a calcium-dependent cross-
linking reaction that forms N-ε (g-glutamyl) lysine
bonds [9-12]. TG2 has been implicated in apoptosis,
although the mechanisms are unknown. Recently, we
demonstrated that TG2 induces caspase-independent
apoptosis in ethanol-treated hepatocytes by crosslinking
and inactivation of the general transcription factor, Sp1,
thereby reducing Sp1-dependent expression of growth
factor receptors [9,13]. However, whether TG2-induced
apoptosis pathway is involved in apoptotic signaling in
other cell types or is induced by stimulation with anti-
cancer reagents remains unclear.
Piedrafita et al. [14] reported that retinoid-induced
apoptosis of T cells accompanies degradation of Sp1
downstream of the caspase pathway. Shao et al. [15]
found that ACR inhibits the growth of HCC cells by
reducing the expression of an Sp1-transactiviable gene,
fibroblast growth factor receptor 3 (FGFR3) [16].
These reports suggest that Sp1 and/or its regulating
genes are important in ACR-induced apoptosis pathway
in HCC cells. We have therefore tested the hypothesis
that ACR can restore the expression of TG2 by prevent-
ing phospho-inactivation of RXRa,a n dd o w n r e g u l a t e
the expression of growth factor receptors by inactivating
Sp1 due to both caspase-dependent degradation and
TG2-dependent crosslinking. We have used HCC cells
in culture and in vivo models of both transplantation of




ACR (NIK-333) was supplied from Kowa Company, Ltd.
(Tokyo, Japan). Anti-TG2 monoclonal antibody (TGase II,
Ab-1) was purchased from NeoMarkers (Fremont, CA).
Anti-TG2 polyclonal antibody was produced as previously
described [13]. Mouse anti-Sp1 (IC6), rabbit anti-Sp1
(PEP2), anti-EGFR, anti-c-Met, anti-FGFR1 antibodies were
bought from Santa Cruz Biotechnology (Santa Cruz, CA).
Mouse anti-GAPDH antibody was from Millipore
(Billerica, MA). Anti-Bcl-XL and anti-cleaved caspase 3
antibodies were from Cell Signaling Technology (Dan-
vers, MA). Horseradish peroxidase (HRP)-conjugated
goat anti-rabbit or mouse IgG was from Jackson Immu-
noResearch Laboratories (West Grove, PA). Viable cells
were measured using a cell counting kit-8 (Dojindo;
Tokyo, Japan). 5-(biotinamido) pentylamine, a biotiny-
lated primary amine substrate for TG2 was provided by
Pierce Biotechnology (Rockford, IL). A caspase-3 specific
inhibitor, zDEVD-fmk, and Hoechst 33258 came from
Calbiochem-Novabiochem (La Jolla, CA). Anti-cross-
linked Sp1 (CLSp1) antibody was made in rabbits, and
purified as previously described [13].
Cells and plasmids
A HCC cell line, JHH-7 cells kindly supplied by
Dr. Matsuura (Jikei University School of Medicine,
Tokyo, Japan) [17] were maintained in ASF104 med-
ium (Ajinomoto, Tokyo, Japan). HC cells, a normal
human hepatocyte cell line purchased from Cell Sys-
tems (Kirkland, WA), were cultured in CS-C complete
m e d i u m( K i r k l a n d ,W A )[ 4 ] .H u H - 7 ,H e p G 2 ,a n d
HelaS3 cells were maintained in RPMI 1640 medium
containing 10% FBS. The expression vector for human
Sp1 (Sp1-pCIneo) was constructed as previously
described [18]. The TG2, Sp1, and EGFR siRNA-
expressing lentiviral vectors were constructed in the
pSIH-H1 shRNA vector (SBI System Biosciences, CA).
A GC3-Luc vector, containing 3 sequential repeats of
GC box motifs derived from the EGFR promoter [19]
and its TATA box sequence upstream of the luciferase
cDNA, was generated by inserting a synthesized oligo-
deoxynucleotide cassette into the pGL3 vector (Pro-
mega Corp., WI).
Transient transfection
Transfections and assays of luciferase activity were per-
formed with a combination of UNIFECTOR lipofection
reagent (B-Bridge International, Inc.; Mountain View,
CA) and luciferase reporter genes (firefly- and Renilla-
Luc) as previously described [20], with further details
being provided in the Additional file 1.
TG2 knockdown
Knockdown of TG2 was performed by transfection of
anti-sense (AS) or siRNA to TG2 in JHH-7 cells, sup-
pressing the expression of TG2 protein ~50% and ~70%,
respectively (Additional file 2 Figure S1)
Preparation of whole lysates and nuclear extracts
Whole lysates were prepared in Hepes buffer containing
10 mM CHAPS and protease inhibitors. Nuclear
extracts were prepared as previously described [20].
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Western blotting was carried out as previously described
[20], using combinations of 1 μg/ml each of anti-Sp1,
anti-CLSp1, or anti-TG2 antibody and HRP-conjugated
goat anti-rabbit/mouse IgG (1:1,000 dilution). Reactants
were detected with Enhanced Chemiluminescence
reagents (GE Healthcare, Buckinghamshire, UK).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
RT-PCR was done as before [18], using sets of specific
primers summarized in Additional file 3 Table S1.
Staining of cells
Cells grown on cover slips were fixed with 10% formalin
in culture medium. They were permeabilized with 0.3%
Triton X-100 in TBS (pH 7.4), and stained with the anti-
bodies given in each figure legend. Apoptosis was
detected by the terminal deoxynucleotidyl transferase-
mediated dUTP nick end-labeling (TUNEL) method
with the In Situ Cell Death Detection Kit (Roche Diag-
nostics GmbH; Mannheim, Germany). Digital images of
cells were obtained by confocal microscope (Carl Zeiss,
Inc. Germany), and digital images recorded.
Animal experiments
One week after JHH-7 cells (2 × 10
6 /50 μl) had been
transplanted into the spleens of nude mice aged 6 weeks
(Balb/c Slc-nu/nu, Japan SLC Inc., Shizuoka, Japan), ACR
(100 mg/kg/day) or vehicle (soybean oil) was admini-
strated by gavage at 10 μl / gb o d yw e i g h to n c ead a yo n
consecutive days for 3 weeks. The DEN-induced rat hepa-
tocarcinogenesis model was used as previously described
[21]. Briefly, 6-week old rats (F344/N SLC; Japan SLC Inc.,
Shizuoka, Japan) were given drinking water containing 40
ppm DEN (Tokyo Kasei Kogyo Co., Tokyo, Japan) for 15
weeks to produce liver neoplasms. ACR (40 and 80 mg/
kg) or vehicle (soybean oil) was administered orally with a
stomach tube at 5 μl/g body weight for 14 weeks. Experi-
ments were performed in accordance with protocols
approved by the RIKEN Institutional Animal Use and the
Care Administrative Advisory Committees.
Immunohistochemistry
Immunohistochemistry were performed as before [13].
Livers were removed, fixed in 10% formalin, and
embedded in paraffin wax. Sections were prepared and
stained with anti-CLSp1, anti-TG2, anti-cleaved caspase
3, and anti-EGFR polyclonal antibodies. Staining signals
were enhanced using an ABC kit (VECTASTAIN) and
developed with DAB substrate.
Statistical analysis
Quantitative data are given as means ± SD. Student’s t
test was used to evaluate differences between 2 groups.
In comparing data from the vehicle group with those
from groups treated with ACR at doses of 25, 50, and
100 mg/kg body weight, the level of serum AFP and the
number of AFP-positive mice were analyzed by
Dunnett’s multiple comparison and Fisher’s exact prob-
ability test, respectively. A p-value of <0.05 was consid-
ered statistically significant.
Results
ACR induces both caspase- and TG2-dependent apoptosis
pathways
ACR induced TUNEL-positive apoptosis of JHH-7 cells,
but not normal hepatocyte HC cells (Figure 1A, left
panel). Apoptotic JHH-7 cells were also positive for
crosslinked Sp1 (CLSp1; Figure 1A, right panel). Strong
immunofluorescent spots were obvious in cells under-
going severe apoptosis (Figure 1A, right panel,a r r o w s ) .
JHH-7 cells were the most sensitive to ACR of the 3
HCC cell lines (JHH-7, HuH-7, HepG2) and HelaS3
cells (Figure 1B). They showed similar TG2/TUNEL/
CLSp1-positive apoptosis following ACR treatment
(data not shown). Consistent with previous findings with
another HCC cell line (HuH-7) [6], ACR treatment of
JHH-7 cells, but not HC cells, suppressed phosphoryla-
tion of RXRa without affecting the expression of RXRa
(Additional file 4 Figure S2A), prevented phospho-inac-
tivation of RXRa,a n de n h a n c e dt h ee x p r e s s i o no fT G 2
(Additional file 4 Figure S2B).
Reciprocally in parallel with a dose- and time-depen-
dent decrease in cell number (Figure 1C, left panels),
both TUNEL (Figure 1C, middle panels)a n dT G 2p o s i -
tivity (Figure 1C, right panels) increased in ACR-treated
JHH-7 cells undergoing apoptosis. ACR-induced apopto-
sis was partially blocked by either the inclusion of the
caspase inhibitor, z-DEVD (Figure 1D and 1E, sample 3)
or knocking down by 50% TG2 expression with anti-
sense (AS) TG2 (Figure 1D and 1E, sample 4; Additional
file 2 Figure S1A), whereas apoptosis was almost com-
pletely blocked by their combined inhibition (Figure 1D
and 1E, sample 5). These results suggest that ACR-
induced apoptosis is dependent on both caspase 3 and
TG2 activation.
In ACR-treated JHH-7 cells ACR had markedly
increased levels of CLSp1 (Figure 1A, right panel and
Additional file 5 Figure S3A, lane 4), whereas levels of
the Sp1 monomer decreased (Additional file 5 Figure
S3A, lane 2), thereby reducing its DNA binding activity
(Additional file 5 Figure S3B) and transactivation activity
(Additional file 5 Figure S3C), as previously seen in
ethanol-induced hepatocyte apoptosis [13]. Impaired
Sp1 activity was partially improved either by inhibition
of caspase or TG2 knockdown by transfection of ASTG,
and almost completely restored by their combination, as
also by overexpression of Sp1. These results suggest that
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Page 3 of 11Figure 1 Induction of caspase 3 and TG2- dependent apoptosis by ACR in JHH-7 cell cultures. A, JHH-7 and HC cells were seeded in
35 mm dishes containing glass coverslips at 2 × 10
5/dish, and treated with 10 μM ACR or vehicle (0.1% ethanol) for 24 h. Cells were fixed and
stained combination with Hoechst 33258, and TUNEL (left panels) or anti-CLSp1 antibody (right panel). Scale bar, 50 μm. B, JHH-7, HuH-7, HepG2
and HelaS3 were seeded at 1 × 10
4 cells/96 well microplates and treated with the indicated concentrations of ACR or vehicle for 24 h. Viable
cell counts are plotted as percentages of each control culture treated with vehicle. C, JHH-7 cells were seeded as before and treated either with
the indicated concentrations of ACR for 48 h, or with 10 μM ACR for the indicated times. Cells were fixed and stained with Hoechst 33258,
TUNEL, and anti-TG2 antibody. The numbers of total and apoptotic cells with TUNEL or TG2 positivity in each dish were counted and plotted. D,
JHH-7 cells were seeded as before and transfected with either pSG5 or anti-sense (AS) TG2-pSG5. The next day cells were treated with either
vehicle or 10 μM ACR for 24 h in the presence or absence of 100 μM zDEVD-fmk, with 1 mM 5-(biotinamido)-pentylamine being included
during the last 2 h incubation. Cells were fixed and stained with Hoechst 33258 (upper panels), TRITC-conjugated streptavidin (middle panels), and
TUNEL (bottom panels). Arrowheads indicate apoptotic cells with chromatin condensation. Scale bar, 50 μm. E, JHH-7 cells were treated as in (C).
The numbers of total and apoptotic cells with TUNEL (green colors) or TG2 (orange colors) positivity in each dish were counted and plotted as
bar graphs. Their percentages relative to total cell number are given on the right hand-side of each bar graph. Panels A-E show representative
results from 3 different experiments with similar results.
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silencing of Sp1 activity, which correlates with cell
viability (Additional file 5 Figure S3D).
Reduced expression of growth factor receptors as the
major Sp1 transcriptional targets in ACR-treated JHH-7
cells undergoing apoptosis
ACR-treated JHH-7 cells expressed decreased levels of
EGFR at both mRNA (Figure 2A; 2.5-fold reduction in
quantitative PCR) and protein (Figure 2B) levels.
Although protein levels of c-Met and FGFR1 remained
largely unaltered, mRNA levels of c-Met and FGFR1
decreased slightly following ACR-treatment. mRNA of
Bcl-XL was unchanged, but moderately altered at the
protein level. ACR induced activation of caspase 3, but
not its expression (Additional file 6 Figure S4A and S4B,
respectively). While a single treatment with either a cas-
pase inhibitor, z-DEVD (Figure 2C, lane 4) or overload-
ing EGF (Figure 2C, lane 6) partially prevented a
reduction in cell number in ACR-treated JHH-7 cells,
combined treatment completely prevented this reduction
(Figure 2C, lane 8).
To determine whether reduced expression of EGFR
was due to Sp1 inactivation, transactivation of a chi-
meric reporter gene-construct in which expression was
driven by 3 tandem functional GC box motifs derived
from the EGFR promoter was monitored. ACR-treat-
ment decreased the transactivational activity of the
EGFR gene promoter (compare Figure 2D, lanes 1 and
2), which was partially prevented by overexpressing Sp1
(compare Figure 2D, lanes 2 and 4) or downregulating
TG2 expression by 70% (compare Figure 2D, lanes 2
and 6; Additional file 2 Figure S1B). It was partially
reversed by overexpression of TG2 (compare Figure 2D,
lanes 2 and 8) and Sp1 inactivation with siRNA (com-
pare Figure 2D, lanes 2 and 10). Sp1 inactivation with
siRNA also reduced expression of EGFR protein (Figure
3A). In hepatocytes, treatment with Sp1 siRNA had pre-
viously decreased cell viability ([13]; data not shown
here). siRNA knockdown of EGFR led to apoptosis
(Figure 3B-3D). These results suggest that transcrip-
tional reduction of EGFR due to a reduction in Sp1
activity may partially explain ACR-induced apoptosis of
HCC cells.
ACR suppresses both transplant of human HCC cells in
nude mice and DEN-induced rat hepatocarcinogenesis by
inducing apoptosis accompanying the emergence of
nuclear TG2 and CLSp1
Finally, the in vivo effect of ACR was examined in the 2
animal models. Using the transplant model in mice,
where ACR dose-dependent reduction of serum levels of
at u m o rm a r k e rf o rH C C ,a-fetoprotein (AFP) and the
incidence of HCC (Additional file 7 Table S2), nuclear
Figure 2 Induction of caspase 3- and TG2-dependent apoptosis
by ACR via a reduction in the expression of EGFR due to
silencing of Sp1. A, JHH-7 cells were treated with 10 μM ACR or
vehicle for 12 h. Cells were harvested and mRNA expression of
indicated genes was determined by RT-PCR. Bar graphs show
densitometrically determined relative mRNA abundance normalized
to GAPDH mRNA levels. **P < 0.01 compared to each control. B,
JHH-7 cells were treated with 10 μM ACR or vehicle for 24 h. Cells
were harvested and protein expression of indicated proteins was
determined by Western blotting. The bar graph shows
densitometrically determined relative protein abundance normalized
to GAPDH protein levels. **P < 0.01 compared to each control. C,
JHH-7 cells were treated with 10 μM ACR for 24 h in the presence
or absence of 100 μM zDEVD, 50 ng/ml EGF or a combination of
the two, and the numbers of viable cells were determined after
trypsinization by Trypan Blue exclusion. Results shown are means ±
SD (n = 3). *P < 0.05, compared to ACR-treated sample from control
cells (lane 2). D, One day after transfection of JHH-7 cells with EGFR
promoter GC3-Luc (1 μg/dish), cells were treated with 10 μM ACR
for 24 h, co-transfected with Sp1 (lanes 3 and 4), TG2 shRNA (lanes 5
and 6), TG2 (lanes 7 and 8), Sp1 shRNA (lanes 9 and 10), and non-
target siRNA (lanes 11 and 12) expression vector, and cell lysates
were prepared. Luciferase activity of each cell lysate was
determined. Results shown are means ± SD (n = 3). *P < 0.05, **P <
0.01 compared to ACR-treated control sample from control cells
(lane 2). Panels A-D show representative results from three different
experiments with similar results.
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ACR-treated nude mice transplanted with the JHH-7
cell line (Figure 4A, panels A and B, respectively)c o m -
pared with adjacent normal liver (Figure 4A, panels D
and E). Significant induction of TG2 and activation of
caspase 3 occurred in metastatic areas in nude mice
transplanted with JHH-7 cells after treatment with ACR
(Figure 4A, panels A and C, respectively). Moreover,
EGFR levels in the metastatic areas were lower than in
normal areas of the same liver (compare Figure 4A,
panels G and J). Similar results were obtained in the rat
model of DEN-induced hepatocarcinogenesis, in which
Figure 3 Induction of apoptosis in JHH-7 cells using Sp1 and EGFR siRNAs. A, JHH-7 cells overexpressing non-target or Sp1 siRNA were
harvested and protein levels of Sp1, EGFR, and GAPDH determined by Western blotting. B, JHH-7 cells overexpressing non-target or 2 kinds of
EGFR siRNAs were harvested and protein levels of EGFR and GAPDH determined by Western blotting. C, Numbers of viable cells were counted
2 days after seeding these cells on 35 mm dishes. Results shown are the number of viable cells relative to the controls, expressed as % ± S.D.
**P < 0.01 compared to control cells. D, The seeded cells on cover slips in 35 mm dishes were fixed and stained with Hoechst (upper panels)
and TUNEL (second panels). Panels A-D show representative results from 3 different experiments with similar results.
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Page 6 of 11Figure 4 Nuclear accumulation of TG2 and CLSp1 observed in the liver of nude mice transplanted with JHH-7 cells, and in DEN-
treated rats with liver cancer after ACR treatment. A, Liver sections including normal (panels D-F and J-L) and metastatic areas (panels A-C
and G-I) from JHH-transplanted nude mice following treatment with ACR were stained with polyclonal anti-TG2 (30 μg/ml; panels A, D), anti-
CLSp1 (30 μg/ml; panels B, E), anti-cleaved caspase 3 (10 μg/ml; panels C, F), anti-EGFR (10 μg/ml; panels G, J), and non-immune antibodies (NI
IgG; 30 μg/ml; panels H, K). B, Liver sections from normal and neoplastic areas in DEN-treated rats following treatment with vehicle or ACR (at 40
and 80 mg/kg) were stained as in Figure 4A. The signals were enhanced with an ABC kit and developed with DAB substrate. Sections were
counterstained with hematoxylin-eosin (HE; Figure 4A, panels I, L, and Figure 4B, bottom panels). Arrows indicate signals under the levels for each
antigen. Scale bar, 50 μm.
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taneous induction of TG2, CLSp1, and activation of cas-
pase 3 occurred in paralleled with a reduction in EGFR
(Figure 4B).
Discussion
The data show that: (i) ACR suppresses the hyper-phos-
phorylation of RXRa, restored its transcriptional func-
tion, and enhanced the expression of TG2 and its
nuclear accumulation, along with caspase 3 activation;
(ii) Sp1 is crosslinked by TG2 and degraded by caspase
3, resulting in loss of its activity; and (iii) expression of
Sp1-regulated target genes, such as EGFR (critical for
cell survival), decrease, culminating in apoptosis of the
cancer cells (Figure 5). The results of in vitro findings
were confirmed by the in vivo models of nude mice
transplanted with JHH-7 cells and DEN-induced hepato-
carcinogenesis in rats (Figure 4). The recurrence of
HCC in these animal models remains to be elucidated.
ACR treatment induced apoptosis in HCC cells (JHH-
7 and HuH-7), but not in normal hepatocyte cells (HC
c e l l s )( F i g u r e1 Aa n d1 B ) .A sac l u et oar e a s o nf o rt h e
difference, we found that both expression and phosphor-
ylation levels of RXRa were much higher in HCC cells
than in HC cells, and that ACR suppressed its phos-
phorylation levels without altering its expression level
(Additional file 4 Figure S2A), as previously shown [5].
In further previous work, we had demonstrated that 2
amino acids in RXRa, T82 and S260, were phosphory-
lated in HCC, but not in HC cells [4]. Therefore, phos-
phorylation of RXRa observed in JHH-7 cells was
referred to as “hyperphosphorylation”. However, RARa
and RARb were phosphorylated not only in JHH-7 cells,
but also in HC cells, and ACR downregulated their
phosphorylation in both cases (Additional file 4 Figure
S2A). Phosphorylation was not detected in the other 3
subtypes of RXR and RAR (Additional file 4 Figure
S2A). Therefore, phosphorylation of RXRa was only
specific in cancer cells, which could be a reason for the
selective apoptosis of cancer cells by ACR treatment.
It is noteworthy that treatment with either antisense
of TG2 or inhibitors of caspase 3 only partially blocked
ACR-induced apoptosis, whereas their simultaneous
inhibition completely prevented apoptosis, suggesting
that TG2 and caspase 3 contribute independently to the
induction of apoptosis (Figure 1D and 1E). We mea-
sured the activity of caspase 3 and TG2 in the presence
of an inhibitor of each other’s enzyme, such as zDEVD
and cystamine. When cystamine suppressed ~50% of
ACR induction in TG2 activity (compare the differences
between lanes 1 and 4 with those between lanes 2 and
5 in Additional file 6 Figure S4D), it suppressed 60% of
ACR induction in caspase 3 activity (compare the differ-
ences between lanes 1 and 4 with those between lanes 2
and 5 in Additional file 6 Figure S4C). On the other
hand, when zDEVD completely suppressed ACR-
induced increase in caspase 3 activity (compare the dif-
ferences between lanes 1 and 4 with those between
lanes 3 and 6 in Additional file 6 Figure S4C), 50% of
an increase in the TG2 activity remained (compare the
differences with lanes 1 and 4 with those between lanes
3a n d6in Additional file 6 Figure S4D). The data sug-
gest that TG2 and caspase 3 influenced each other with
a higher hierarchy of TG2 over caspase 3 in the contri-
bution to the apoptosis of HCC induced by ACR. Syner-
gism between inhibition in caspase and overloading
of EGF in preventing apoptosis also suggests that both
the caspase 3- and EGFR-dependent pathways exist
(Figure 2C).
Expression of EGFR is regulated by Sp1 [19,22], and
inhibition of EGFR signaling leads to growth inhibition,
apoptosis, and cell cycle arrest of HCC cells [23,24]. We
have linked these findings by showing that the downregu-
lation of EGFR with siRNA induces apoptosis (Figure 3B-
D), suggesting that inhibiting EGFR signaling via silen-
cing Sp1 is a promising treatment strategy against HCC.
Induction of CLSp1 and the subsequent reduction in
EGFR has been reproduced in ACR-treated HuH-7 cells
(data not shown). In contrast, although Shao et al. [15]
reported that ACR inhibits the cell growth through
downregulation of FGFR3 expression and FGF-mediated
signaling in HepG2 cells, this was not found to be the
case in our ACR-treated JHH-7 cells (data not shown).
These findings suggest that HCC cell lines differ in the
way that growth factor receptors are involved in
survival.
Figure 5 Schematic diagram showing the molecular
mechanism by which ACR causes HCC apoptosis by restorating
phospho-inactivated RXRa followed by enhanced TG2-
mediated crosslinking/silencing of Sp1, thereby reducing EGFR-
medicated EGF signaling.
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apoptosis of thymocytes, resulting in loss of transami-
dating function [25], TG2 in turn inhibits of apoptosis
due to crosslinking and inactivation of caspase 3 in
thapsigargin-mediated apoptosis of colon carcinoma
cells [26]. In the latter article, thapsigargin treatment
generated 2 additional biologically inactive species of
caspase 3, viz. p40 and p64, via TG2-mediated crosslink-
ing of caspase 3, thereby protecting cells from apoptosis.
However, we failed to detect either p40 or p64 in our
ACR-treated JHH-7 cells. We speculate that crosslinking
of caspase 3 would be induced specifically by treatment
with thapsigargin. Our data clearly shows that both cas-
pase 3 and TG2 are functional in ACR-treated HCC
cells, without apparent alteration of caspase 3 expression
(Additional file 6 Figure S4A and 4B). These controver-
sial results might be ascribed to differences in cell types
and the nature of the apoptotic stimuli, although the
precise mechanisms need to be elucidated.
Piedrafita and Pfahl [14] reported that caspase 3
directly cleaved and inactivated Sp1 in retinoid-treated
T cells undergoing apoptosis. They showed that clea-
vages of PARP and Sp1 were simultaneously induced by
caspase 3 and prevented with caspase inhibitors (zVAD-
fmk and zDEVD-fmk). We anticipated that CLSp1
might also be partially cleaved by caspase 3; however, as
molecular size differences would be too small to be
recognized on the gel against a high molecular weight of
CLSp1 detected at the top of the gel, we found no band
shifts due to the cleavage. Hence, the possibility of
simultaneous crosslinking and cleavage of Sp1 by TG2
and caspase 3, respectively, cannot be ruled out, even
though we saw no truncated Sp1 with a Mw of 68 kD
in ACR-treated HCC cells.
ACR-treated JHH show enhanced nuclear localization
of TG2; nuclear localization of TG2 is also important
for induction of TG2-dependent apoptosis. Peng et al.
[27] reported that TG2 binds importin-a3, an important
factor in nuclear translocation, and therefore we are
investigating the detail mechanism of TG2 nuclear loca-
lization accompanying ACR-induced apoptosis.
Conclusions
Our new findings indicate that ACR induces both
activation of caspase 3 as well as the expression and
activation of TG2, which together initiate the apopto-
tic pathway via degrading/crosslinking and inactivation
of the transcription factor, Sp1. Reduced expression
of growth factor receptor genes (e.g.E G F R )a l s o
occurs. This dual activation of both caspase and TG-
dependent apoptotic pathways could in part be central
as mechanisms by which ACR inhibits tumor cell
growth, resulting in the prevention of secondary
tumors after treatment of primary HCCs (Figure 5).
Future study should establish the possibility that
regulation of TG2-dependent apoptotic pathway may
help in the development of new therapies for the
prevention of HCC.
Additional material
Additional file 1: Additional text. This text contains the additional
“Methods” and “References”
Additional file 2: Figure S1: Efficiency of transfection with anti-
sense and siRNA to TG2 in JHH-7 cells. A, JHH-7 cells were seeded in
60 mm dishes at 6 × 10
5/dish, and transfected with 4 μg of either empty
vector (pSG5) or ASTG2-pSG5. Cells were harvested and the expression
level of TG2 determined by Western blotting. Upper numbers in
parentheses show the densitometrically determined relative protein
abundance. B, JHH-7 cells were seeded in 60 mm dishes at 6 × 10
5/dish,
and transfected with 4 μg of vectors expressing either non-target siRNA
or TG2 siRNA. Cells were harvested and the expression level of TG2
determined by Western blotting. Upper numbers in parentheses show
the densitometrically determined relative protein abundance. Panels A
and B show representative results from 3 different experiments with
similar results.
Additional file 3: Table S1: Primers for RT-PCR and quantitative-PCR
experiments. The list of used specific primers for RT-PCR.
Additional file 4: Figure S2: ACR prevented phosphorylation and
inactivation of RXRa, and stimulated the expression of TG2 in JHH-
7 cells. A, JHH-7 cells (lane 1 and 2) and HC cells (lane 3 and 4)w e r e
treated with 10 μM ACR or vehicle for 12 h. Cells were harvested and
nuclear extracts were prepared. Phosphoproteins affinity-purified from
each nuclear extract using the Phosphoprotein Purification Kit (QIAGEN)
(left panel) as well as whole nuclear extracts (right panel), were subjected
to SDS-PAGE, followed by Western blotting using the indicated
antibodies against 6 different RXR/RAR or GAPDH. B, JHH-7 cells were
transfected with either an empty vector (columns 1-4) or vectors
expressing wild-type RXRa (columns 5-8), its alanine mutant T82A
(unphosphorylated form; columns 9-12), or its aspartate mutant T82 D
(phosphomimic; columns 13-16). The next day cells were treated either
with 9-cis RA (9cRA; 6 μM) or its vehicle, or with and/or ACR (10 μM) for
24 h. Subsequently, levels of TG2 mRNA in cell lysates were quantified by
RT-PCR (upper panels) and quantitative-PCR (lower graphs), where relative
expression levels of TG2 were calculated in comparison with each
control and then plotted. Treatment with 1 μM 9-cis-RA also gave
basically similar results (data not shown), but the data obtained under
treatment with 6 μM 9-cis-RA are shown here, giving the more
significant differences. Panels A and B show representative results from 3
different experiments with similar results.
Additional file 5: Figure S3: Crosslinking and silencing of Sp1 in
ACR-treated JHH-7 cell cultures undergoing apoptosis and its
reversion by overexpression of Sp1. A, JHH-7 cells were treated with
10 μM ACR for 24 h. The cells were harvested and nuclear extracts
prepared. The levels of Sp1 and CLSp1 were assessed by Western
blotting with an anti-Sp1 (columns 1 and 2) and CLSp1 (columns 3 and 4)
antibodies, respectively. B, JHH-7 cells were transfected with 1.5 μgo f
either combination of pCIneo, pSG5, Sp1-pCIneo,o ranti-sense (AS) TG2-
pSG5. The next day they were treated with either 10 μM ACR or its
vehicle in the presence or absence of 100 μM zDEVD-fmk for 24 h. Cells
were harvested and nuclear extracts prepared. Sp1 DNA-binding activity
of each nuclear extract (10 μg protein) was determined by gel-shift
assay, using a consensus GC box as a probe (+cold; nuclear extracts +
50-fold excess of unlabeled probe, +anti-Sp1 IgG; nuclear extracts + 2 μg
of anti-Sp1 antibody, +NI IgG; nuclear extracts + 2 μg of non-immune
IgG). C, JHH-7 cells were transfected with 1.5 μg of a consensus GC3-Luc
reporter and Renilla-Luc, plus a combination of pCIneo, pSG5, Sp1-pCIneo
or anti-sense (AS) TG2-pSG5. The next day the cells were treated with 10
μM ACR for 24 h in the presence or absence of 100 μM zDEVD-fmk. Cell
lysates were prepared and luciferase activity of each cell lysate
determined. Results are means ± SD (n = 3). D, JHH-7 cells were
Tatsukawa et al. Molecular Cancer 2011, 10:4
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Page 9 of 11transfected with either a combination of pCIneo, pSG5, anti-sense (AS)
TG2-pSG5, Sp1-pCIneo, Sp1 C domain-pCIneo, ΔC Sp1-pCIneo. The next day
the cells were treated with 10 μM ACR for 24 h. The number of viable
cells was determined. Results are means ± SD (n = 4). Panels A-D show
representative results from 3 different experiments with similar results.
Additional file 6: Figure S4: ACR stimulated activation of caspase 3
and TG2 in JHH-7 cells and the crosstalk between these proteins. A
and B, JHH-7 cells were treated with 10 μM ACR or the vehicle for 24 h.
Cells were harvested and protein levels of activated caspase 3 and
GAPDH determined by Western blots, using anti-cleaved-caspase 3 and
anti-GAPDH antibodies (A); each of their mRNA expression was
determined by RT-PCR (B). C, JHH-7 cells was seeded at 1 × 10
4 cells/96
well microplates and treated with 10 μM ACR or vehicle (0.1% ethanol)
for 5 h in the presence or absence of either 100 μM zDEVD-fmk or 100
μM cystamine with 0.2 mM 5-(biotinamido)-pentylamine. Caspase 3
activity was measured using a Caspase-Glo 3/7 assay kit (Promega Corp.,
WI) as described in attached manual. Relative caspase 3 activity of each
sample was calculated by normalization with the number of viable cells
in the same sample measured with a cell counting kit-8 (Dojindo; Tokyo,
Japan). D, JHH-7 cells seeded in 100 mm dishes at 1.6 × 10
6/dish were
treated as in (C). TG2 activity was measured as described in Additional
file 1. Relative TG2 activity of each sample was calculated by
normalization with the number of viable cells in the same sample,
measured with a cell counting kit-8 (Dojindo; Tokyo, Japan). Panels A-D
show representative results from 3 different experiments with similar
results.
Additional file 7: Table S2: Suppression by ACR of metastasis and
growth of human HCC cell line, JHH-7 cells transplanted into nude
mice. Nude mice that had been transplanted with JHH-7 were given
orally with ACR with increasing concentrations (25, 50, and 100 mg/kg/
day) as described detailed in the “Methods”. Serum AFP was measured.
Incidence was calculated based on level of the positive-AFP (more than
6 ng/ml). Cisplatin was used as a positive control. *p < 0.05 compared to
control (Dunnett’s multiple comparison test), #p < 0.05 compared to
control (Fisher exact test)..
List of abbreviations
9-cis RA: 9-cis retinoic acid; ACR: acyclic retinoid; CLSp1: crosslinked Sp1;
DEN: N-diethylnitrosamine; EGFR: epidermal growth factor receptor; FGFR3:
fibroblast growth factor receptor 3; HCC: hepatocellular carcinoma; RXR:
retinoid X receptor; TG2: transglutaminase 2.
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